TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01249430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02186223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Angel® Catheter
Description: The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
Study: NCT04238065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caterna Virtual Reality
Description: Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles(Best optical corrected distance vision)
Description: Each eye has best corrected vision spectacles with best corrected optical lens.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spectacles(Best optical corrected distance vision)
Description: Each eye has best corrected vision spectacles with best corrected optical lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch
Description: 2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Patch
Description: 2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
Study: NCT04454177

Intervention type: DEVICE
Intervention: HUAWEI watch
Description: HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering.
Study: NCT01553097

Intervention type: OTHER
Intervention: Neurocognitive impairment observation
Description: None - observational

Intervention type: OTHER
Intervention: Neurocognitive impairment observation
Description: None - observational

Intervention type: OTHER
Intervention: Neurocognitive impairment observation
Description: None - observational
Study: NCT02804776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250mg oral daily for 4 weeks
Study: NCT01545570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2376497
Description: GSK2376497 Active Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 0.9% sodium chloride Placebo Comparator
Study: NCT04677868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
Study: NCT03668353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SeV-hFGF2/dF Injection
Description: intramuscular injection of investigator drugs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SeV-hFGF2/dF Injection
Description: intramuscular injection of investigator drugs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SeV-hFGF2/dF Injection
Description: intramuscular injection of investigator drugs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SeV-hFGF2/dF Injection
Description: intramuscular injection of investigator drugs
Study: NCT02066428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404
Description: AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
Study: NCT02137720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic Diabetes Self-Management Support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Print Materials
Study: NCT01470313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0360324
Description: Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
Study: NCT01143974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed plus cisplatin
Description: pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
Study: NCT02947776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEER
Description: The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USUAL
Description: The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: USUAL
Description: The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
Study: NCT00234546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 1 injection, 500 U at day 0. The study will last for 6 months in each patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 injection at day 0. The study will last for 6 months in each patient.
Study: NCT02715154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
Study: NCT03111251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider assessment and feedback
Description: Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider assessment and feedback
Description: Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider reminders
Description: An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider reminders
Description: An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider education
Description: Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider education
Description: Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reminders
Description: Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reminders
Description: Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent education
Description: The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
Study: NCT05040477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy Technique
Description: Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy.
Study: NCT05040477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy Technique
Description: Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy Technique
Description: Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy.
Study: NCT02855424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the low-intensity exercise group
Description: Totally 20-time training, frequency 2-6 time/week, total 20 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the moderate-intensity exercise group
Description: Totally 20-time training, frequency 2-6 time/week,total 20 times.
Study: NCT02079610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback: Amygdala
Description: Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: real-time fMRI neurofeedback: HIPS
Description: Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
Study: NCT02482870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision video laryngoscope
Description: Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision video laryngoscope
Description: Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
Study: NCT01620255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC Injection
Description: Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC Injection
Description: Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC Injection
Description: Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC Injection
Description: Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
Study: NCT04508231

Intervention type: OTHER
Intervention: Gender-affirming hormone therapy
Description: Gender-affirming hormone therapy according to the recommendations of the Endocrine Society
Study: NCT05787028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg
Description: Take one AD16 tablet in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg
Description: Participants will take a placebo pill matching AD16 once in the morning
Study: NCT04362605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Negative Pressure Therapy
Description: In patients with suspected insufficiency of the esophagojejunostomy first an index endoscopy under general anesthesia with endotracheal intubation was indicated. Standard gastroscopes with outer diameter of 9.8mm were used with carbon dioxide insufflation.~Definition of a anastomotic leak were endoscopic or radiological dehiscences at the esophagojejunostomy with extravasation of fluids and gas. In cases of insufficiencies start of endoluminal ENPT were indicated.~Decision criteria for placement of OPD or OFD were the defect size, radiological findings and clinical situation of the patient. A CT scan in patients with suspected EJAL was done in all cases.~For endoluminal ENPT, the open-pore drainage system is placed within the lumen of the digestive tract at the entrance to the cavity.
Study: NCT02774161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Tomography
Description: Undergo B-mode ultrasound imaging
Study: NCT03681704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuangQi Decoction
Description: HuangQi Decoction 150ml twice a day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HuangQi Decoction placebo
Description: traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
Study: NCT02306486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: with 0,5% oxalic acid (Desenssiv SSWhite)
Description: with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: with 0,5% oxalic acid (Desenssiv SSWhite)
Description: with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
Study: NCT02954640

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Additional blood sampling for the realization of the test on the gene panel
Study: NCT00551811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933-AAA
Description: SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be intended to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be intended to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be intended to be administered orally.
Study: NCT03011502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples collection of blood and feces
Study: NCT02808637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Pressure
Description: First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Injection without Aspiration
Description: First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Pressure + Rapid Injection without Aspiration
Description: First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.